Dr Nick Maisey

Oncologist, Consultant Medical Oncologist, Guy's and St Thomas’ NHS Foundation Trust (GSTT)
  • London, United Kingdom
  • En
  • Best at: Bowel, oesophageal, stomach cancers, carcinoma of unknown primary & GIST

Dr Maisey is a consultant in Medical Oncology at Guy's and St Thomas’ NHS Foundation Trust (GSTT). He currently leads Medical Oncologist for oesophago-gastric cancer at GSTT and has held a number of key roles including service lead for colorectal cancer, vice chair of the upper gastrointestinal tumour working group and medical director for the South East London Cancer Network. He is currently a core member of the Oesophago-gastric priority group for the London Cancer Alliance, overseeing the delivery of care across North-West, South-West and South-East London. He is also a core member of the Carcinoma of unknown primary team at Guy's and St Thomas and have been instrumental in developing the service of treatments and pathways for this rare cancer. Dr Maisey is involved in cancer drug development and has been a principal investigator on a number of national clinical trials as well as commercial studies. After qualifying in 1993 from Guy's and St Thomas’ Hospital, he became a member of the Royal College of Physicians 1997. He completed his specialist training in medical oncology at the Royal Marsden Hospital. During his specialist training he was successful in a competitive grant from the National Cancer Institute to perform research at the Institute of Cancer Research in London. In 2002 he was awarded an MD thesis for his work on early response markers in Cancer.

Statistics.

Achievements of Dr Nick Maisey

Trustedoctor credentials
-
Clinical endorsements
10
Articles
83
Scientific
co-authors
Trustedoctor credentials
19
General specialty
5
Subspeciality
Languages

About.

Information about Dr Nick Maisey

Timeline
Place
Country
Position
Focus
Since 2013
Guys Hospital
United Kingdom
-Bachelor of Medicine, Bachelor of Surgery (MBBS) Field Of StudyMedicine
Oncology
Since 2013
Independent Practice Services
United Kingdom
Director
Business Practice
Since 2004
Guy's and St. Thomas' NHS Foundation Trust
United Kingdom
Consultant Medical Oncologist
Oncology
1996 - 2004
The Royal Marsden NHS Foundation Trust
United Kingdom
Specialist Registrar
Oncology
Timeline
Place
Country
Position
Focus
Independent Oncology
United Kingdom
Clinical Lead
Oncology (GI)
-
-
United Kingdom
-
-
-
-
United Kingdom
-
-
Timeline
Place
Organization
Position
-
United Kingdom
British Medical Association
Member
-
United Kingdom
Association of Cancer Physicians
Member
-
United States
American Society of Clinical Oncology
Member
-
Europe
European Society of Medical Oncology
Member
Timeline
Description
Collaboration
-
-
-
Timeline
Place
Award
Position
-
-
-
-

Clinical Experience.

General speciality (5)
Patients per year
Patients total
general pancreas tumour oncology
0-50
-
chemotherapy
0-50
-
targeted therapy
0-50
-
experimental therapy
0-50
-
clinical trials
0-50
-
Tumor speciality (2)
Patients per year
Patients total
pancreatic ductal adenocarcinoma
0-50
-
fibrolamellar carcinoma
0-50
-
General speciality (6)
Patients per year
Patients total
general colorectal tumour oncology
0-50
-
chemotherapy
0-50
-
targeted therapy
0-50
-
experimental therapy
0-50
-
clinical trials
0-50
-
general colorectal tumour oncology
0-100
-
Tumor speciality (1)
Patients per year
Patients total
adenocarcinoma
0-100
-
General speciality (5)
Patients per year
Patients total
general stomach tumour oncology
0-50
-
chemotherapy
0-50
-
targeted therapy
0-50
-
experimental therapy
0-50
-
clinical trials
0-50
-
Tumor speciality (2)
Patients per year
Patients total
gastrointestinal stromal tumours (gists)
0-50
-
adenocarcinoma
0-50
-
General speciality (3)
Patients per year
Patients total
general esophageal tumour oncology
0-50
-
chemotherapy
0-50
-
targeted therapy
0-50
-
Techniques (2)
Patients per year
Patients total
experimental therapy
0-50
-
clinical trials
0-50
-

Skills & Endorsements.

General specialty
general pancreas tumour oncology
chemotherapy
targeted therapy
experimental therapy
clinical trials
General specialty
clinical trials
experimental therapy
targeted therapy
chemotherapy
general colorectal tumour oncology
General specialty
general stomach tumour oncology
chemotherapy
targeted therapy
experimental therapy
clinical trials
General specialty
general esophageal tumour oncology
chemotherapy
targeted therapy
Techniques
experimental therapy
clinical trials

Academic research.

10
Total articles
  • oncology - 8
  • chemotherapy - 5
3
colorectal cancer articles - Impact Factor
  • gastrointestinal tract - 3
  • oncology therapy - 3
3
oesophageal cancer articles - Impact Factor
  • Oseophagus - 3
  • oncology therapy - 3
Tumor stage after neoadjuvant chemotherapy determines survival after surgery for adenocarcinoma of the esophagus and esophagogastric junction.

Neoadjuvant chemotherapy is established in the management of most resectable esophageal and esophagogastric junction adenocarcinomas. However, assessing the downstaging effects of chemotherapy and predicting response to treatment remain challenging, and the relative importance of tumor stage before and after chemotherapy is debatable.

Assessment of sarcopenia and changes in body composition after neoadjuvant chemotherapy and associations with clinical outcomes in oesophageal cancer.

Sarcopenia and changes in body composition following neoadjuvant chemotherapy (NAC) may affect clinical outcome. We assessed the associations between CT body composition changes following NAC and outcomes in oesophageal cancer.

Video.

My recent video

Connections.

Map of connections

83
Scientific
co-authors
Our website unfortunately does not support your browser.<br/>Please click <a href="https://www.google.com/chrome/">here</a> to download and install new browser.
Supported browsers: Firefox, Chrome, Opera.